Chris Viehbacher, Biogen CEO (Photo by Suzanne Kreiter/The Boston Globe via Getty Images)
April 24, 2024 11:18 AM EDT
Pharma

8 take­aways from Bio­gen’s Q1 up­date: A ‘dif­fi­cult’ launch for Leqem­bi, a $103M vouch­er and a fo­cus on new li­cens­ing deals

Kyle LaHucik

Senior Reporter

Bio­gen’s lead­ers de­fend­ed their Ei­sai-part­nered Leqem­bi dur­ing a first-quar­ter earn­ings up­date on Wednes­day, say­ing the Alzheimer’s treat­ment is on a path to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times